The Drug Development Unit provides a key link between The Institute of Cancer Research’s Cancer Research UK Cancer Therapeutics Unit and The Royal Marsden NHS Foundation Trust Tumour Teams. The Unit’s primary responsibility is for first-in-man phase I trials of novel agents. These involve a range of targets, including growth factor or intracellular signalling, angiogenesis, apoptosis, epigenetics and DNA repair. All trials are underpinned by extensive analysis of biomarkers, both predictive and pharmacodynamic.
There are strong links to other ICR teams, notably the Prostate Cancer Targeted Therapy Group (Head: Professor Johann de Bono).